Regdanvimab - CISMeF

Preferred Label : Regdanvimab;

NCIt definition : A neutralizing, human immunoglobulin G1 (IgG1) monoclonal antibody directed against the spike (S) protein receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against Coronavirus disease 2019 (COVID-19). Upon administration, regdanvimab specifically targets and binds to the RBD of the SARS-CoV-2 S protein. This blocks viral attachment and entry into human host cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may also provide temporary protection against infection with SARS-CoV-2. S-protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : I0BGE6P6I6;

CAS number : 2444308-95-4;

Molecule name : CTP 59; CTP-59;

NCI Metathesaurus CUI : CL1642822;

Details

Origin ID

C177084;

UMLS CUI

C5432268;

Currated CISMeF NLP mapping
- regdanvimab [MeSH Supplementary Concept]
- regdanvimab [MeSH concept]
See also inter- (CISMeF)
- COVID-19 [MeSH Descriptor]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- regdanvimab [MeSH Supplementary Concept]
- regdanvimab [ATC Code]
Validated automatic mappings to BTNT
- regdanvimab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients